TY - JOUR
T1 - Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire
T2 - The MINDSET study
AU - Rozema, Johanne
AU - van Roon, Eric
AU - Vogelzang, Lars
AU - Kibbelaar, Robby
AU - Veeger, Nic
AU - van de Loosdrecht, Arjan
AU - Hoogendoorn, Mels
N1 - Funding Information: The authors would like to thank the haematologists in the Netherlands for their cooperation and Jetske Graafsma (University of Groningen, the Netherlands) for her support in the design of the questionnaire. Publisher Copyright: © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2022/10
Y1 - 2022/10
N2 - Objectives: Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case vignette study and to assess the availability of guidelines. Methods: We conducted a web-based, nationwide survey amongst haematologists in the Netherlands between September and December 2021. The survey included a set of case vignettes. In addition, the availability of protocols was evaluated. Results: Sixty responses were obtained (23.6%). These responses were well distributed across hospital types as well as level of experience. No protocols regarding infection prophylaxis specifically for MDS patients were received. In the case vignette of a 75-year-old MDS patient, respondents would primarily prescribe infection prophylaxis in case of recurrent infections (96.7%) and neutropenia (75.0% for absolute neutrophil count [ANC] < 0.2 × 10 9/L and 53.3% for ANC < 0.5 × 10 9/L), especially in combination with hypomethylating agents (80.0%), lenalidomide (66.7%) or chemotherapy (51.7%). Respondents would predominantly choose antibacterial agents (85.0%), followed by antifungal agents (71.7%). Conclusions: This study showed diverse reasons and considerations of haematologists regarding whether to prescribe infection prophylaxis in MDS patients. Given the seriousness of infections in MDS patients, patient-tailored recommendations might be valuable in clinical decision-making.
AB - Objectives: Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case vignette study and to assess the availability of guidelines. Methods: We conducted a web-based, nationwide survey amongst haematologists in the Netherlands between September and December 2021. The survey included a set of case vignettes. In addition, the availability of protocols was evaluated. Results: Sixty responses were obtained (23.6%). These responses were well distributed across hospital types as well as level of experience. No protocols regarding infection prophylaxis specifically for MDS patients were received. In the case vignette of a 75-year-old MDS patient, respondents would primarily prescribe infection prophylaxis in case of recurrent infections (96.7%) and neutropenia (75.0% for absolute neutrophil count [ANC] < 0.2 × 10 9/L and 53.3% for ANC < 0.5 × 10 9/L), especially in combination with hypomethylating agents (80.0%), lenalidomide (66.7%) or chemotherapy (51.7%). Respondents would predominantly choose antibacterial agents (85.0%), followed by antifungal agents (71.7%). Conclusions: This study showed diverse reasons and considerations of haematologists regarding whether to prescribe infection prophylaxis in MDS patients. Given the seriousness of infections in MDS patients, patient-tailored recommendations might be valuable in clinical decision-making.
KW - anti-infective agent
KW - infections
KW - myelodysplastic syndromes
KW - prophylaxis
KW - survey
UR - http://www.scopus.com/inward/record.url?scp=85133435327&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/ejh.13820
DO - https://doi.org/10.1111/ejh.13820
M3 - Article
C2 - 35753043
SN - 0902-4441
VL - 109
SP - 381
EP - 387
JO - European journal of haematology
JF - European journal of haematology
IS - 4
ER -